Benzinga's Top Pre-Market Losers

Nektar Therapeutics (NASDAQ: NKTR ) dipped 24.19% to $10.50 in the pre-market session after the company reported that the results from Phase 2 trial of NKTR-181 missed primary efficacy endpoint. Zoltek Companies (NASDAQ: ZOLT ) shares dropped 10.05% to $16.65 in pre-market trading after Toray Industries agreed to buy